Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Increase in Short Interest

Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 4,010,000 shares, an increase of 76.7% from the March 31st total of 2,270,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is presently 1.6 days.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James began coverage on Aquestive Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $7.00 target price for the company. Piper Sandler began coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They set an “overweight” rating and a $10.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, April 5th. Finally, JMP Securities raised their price objective on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $8.00.

Insider Transactions at Aquestive Therapeutics

In other news, insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the transaction, the insider now owns 984,476 shares of the company’s stock, valued at $5,906,856. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 8.39% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AQST. Jump Financial LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at $60,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Aquestive Therapeutics by 14.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock valued at $379,000 after purchasing an additional 30,898 shares during the last quarter. PFG Investments LLC bought a new stake in Aquestive Therapeutics in the first quarter valued at about $204,000. Legato Capital Management LLC bought a new stake in Aquestive Therapeutics in the fourth quarter valued at about $688,000. Finally, Acadian Asset Management LLC increased its holdings in Aquestive Therapeutics by 238.8% in the third quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock valued at $841,000 after purchasing an additional 388,017 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Stock Up 3.6 %

Shares of Aquestive Therapeutics stock traded up $0.14 during trading on Friday, hitting $4.07. 2,986,647 shares of the stock traded hands, compared to its average volume of 2,312,568. Aquestive Therapeutics has a twelve month low of $1.19 and a twelve month high of $6.23. The company has a fifty day moving average price of $4.17 and a two-hundred day moving average price of $2.81.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to analyst estimates of $11.79 million. On average, equities research analysts expect that Aquestive Therapeutics will post -0.36 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.